Page 36 - Read Online

Ji et al. Rare Dis Orphan Drugs J 2023;2:26 https://dx.doi.org/10.20517/rdodj.2023.30 Page 19 of 19

83. Lakes KD, Vaughan E, Lemke A, et al. Maternal perspectives on the return of genetic results: context matters. Am J Med Genet A
2013;161A:38-47. DOI PubMed PMC
84. Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassaemic care & control in India. Indian J Med Res
2011;134:507-21. PubMed PMC
85. Medical Services Advisory Committee. About MSAC. Available from: http://msac.gov.au/internet/msac/publishing.nsf/Content/
about-msac [Last accessed on 21 Nov 2023].
86. Medical Services Advisory Committee. Guidelines for preparing assessments for the Medical Services Advisory Committee.
Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/E0D4E4EDDE91EAC8CA2586E0007AFC75/$File/
MSAC%20Guidelines-complete-16-FINAL(18May21).pdf [Last accessed on 21 Nov 2023].
87. Potter BK, Avard D, Entwistle V, et al. Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional
and newborn screening: a workshop report. Public Health Genomics 2009;12:4-10. DOI PubMed PMC
88. Potter BK, Avard D, Graham ID, et al. Guidance for considering ethical, legal, and social issues in health technology assessment:
application to genetic screening. Int J Technol Assess Health Care 2008;24:412-22. DOI
89. Rahimzadeh V, Friedman JM, de Wert G, Knoppers BM. Exome/genome-wide testing in newborn screening: a proportionate path
forward. Front Genet 2022;13:865400. DOI PubMed PMC
90. Pharmaceutical Benefits Advisory Committee. About the guidelines. Available from: https://pbac.pbs.gov.au/information/about-the-
guidelines.html [Last accessed on 21 Nov 2023].
91. Medical Services Advisory Committee. Application No. 1573 - reproductive carrier testing for cystic fibrosis, spinal muscular
atrophy and fragile X syndrome. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/
4EF0E3C5A7CC9D05CA2584240009557E/$File/1573%20-%20Final%20PSD_Jul2020.pdf [Last accessed on 21 Nov 2023].
92. Medical Services Advisory Committee. Application No. 1637 - expanded reproductive carrier testing of couples for joint carrier
status of genes associated with autosomal recessive and X-linked conditions. Available from: http://www.msac.gov.au/internet/msac/
publishing.nsf/Content/58B9ED94DEC5BCDECA2586D500054D7E/$File/1637%20Final%20PSD_Jul2022_redacted_
UpdatedConsultation_clean.pdf [Last accessed on 21 Nov 2023].
93. Ulph F, Bennett R. Psychological and ethical challenges of introducing whole genome sequencing into routine newborn screening:
lessons learned from existing newborn screening. New Bioeth 2023;29:52-74. DOI PubMed
94. Williams WA 2nd, Ross LF. The Harms of Carrier Status Identification: a cautionary warning against newborn sequencing. J Pediatr
2020;224:22-3. DOI
95. Goldenberg AJ, Lloyd-Puryear M, Brosco JP, et al; Bioethics and Legal Workgroup of the Newborn Screening Translational
Research Network. Including ELSI research questions in newborn screening pilot studies. Genet Med 2019;21:525-33. DOI
96. Currier RJ. Newborn screening is on a collision course with public health ethics. Int J Neonatal Screen 2022;8:51. DOI PubMed
PMC
97. Kemper AR, Boyle CA, Brosco JP, Grosse SD. Ensuring the life-span benefits of newborn screening. Pediatrics
2019;144:e20190904. DOI PubMed PMC
98. Sen K, Harmon J, Gropman AL. Select ethical aspects of next-generation sequencing tests for newborn screening and diagnostic
evaluation of critically Ill newborns. Int J Neonatal Screen 2021;7:76. DOI PubMed PMC
99. Clark CC, Boardman FK. Expanding the notion of “benefit”: comparing public, parent, and professional attitudes towards whole
genome sequencing in newborns. New Genetics and Society 2022;41:96-115. DOI
100. Yang L, Chen J, Shen B. Newborn screening in the era of precision medicine. In: Shen B, editor. Translational informatics in smart
healthcare. Singapore: Springer; 2017. pp. 47-61. DOI